2-[(1S)-2-cyclohexyl-1-methylethyl]-1H-isoindole-1,3(2H)-dione | 929117-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[(1S)-2-cyclohexyl-1-methylethyl]-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-[(2S)-1-cyclohexylpropan-2-yl]isoindole-1,3-dione
• CAS: 929117-24-8
• 化学式: C₁₇H₂₁NO₂
• 分子量: 271.359
• InChiKey: AKYJQZPFGZFNCH-LBPRGKRZSA-N

物化性质

• 沸点：
  393.7±11.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-[(1S)-2-cyclohexyl-1-methylethyl]-1H-isoindole-1,3(2H)-dione 在 platinum(IV) oxide 、 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 肼 作用下， 以 四氢呋喃 、 甲醇 、 溶剂黄146 为溶剂， 反应 2.0h， 生成 N-((S)-2-Cyclohexyl-1-methyl-ethyl)-2-methylamino-acetamide
  参考文献：
  名称：

  Acyclic cyanamide-based inhibitors of cathepsin K

  摘要：

  Conversion of the proline-derived cyanamide lead to an acyclic cyanamide capable of forming an additional hydrogen bond with cathepsin K resulted in a large increase in inhibitory activity. An X-ray structure of a co-crystal of a cyanamide with cathepsin K confirmed the enzyme interaction. Furthermore, a representative acyclic cyanamide inhibitor 6r was able to attenuate bone resorption in the rat calvarial model.

  DOI：

  10.1016/j.bmcl.2005.04.032
• 作为产物：
  描述：

  (R)-1-Cyclohexyl-propan-2-ol 、 邻苯二甲酸亚胺 在 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 以93%的产率得到2-[(1S)-2-cyclohexyl-1-methylethyl]-1H-isoindole-1,3(2H)-dione
  参考文献：
  名称：

  Acyclic cyanamide-based inhibitors of cathepsin K

  摘要：

  Conversion of the proline-derived cyanamide lead to an acyclic cyanamide capable of forming an additional hydrogen bond with cathepsin K resulted in a large increase in inhibitory activity. An X-ray structure of a co-crystal of a cyanamide with cathepsin K confirmed the enzyme interaction. Furthermore, a representative acyclic cyanamide inhibitor 6r was able to attenuate bone resorption in the rat calvarial model.

  DOI：

  10.1016/j.bmcl.2005.04.032

文献信息

• [EN] ISOINDOLE DERIVATIVES AS ANTIMICROBIAL AGENTS<br/>[FR] DERIVES D'ISOINDOLE UTILISES EN TANT QU'AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2007029076A1

  公开（公告）日：2007-03-15

  [EN] Provided herein are substituted aromatic compound of Formula (I), which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds disclosed herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal organisms, more particularly against bacterium, for example, Staphylococci, Enterococci, Streptococci, Haemophilus, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus or Enterobactericeae, and fungal organisms, for example, Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Paecilomyces, Paracoccidiodes, Pneumocystis, Trichophyton,or Trichosporium.Processes for the preparation of these compounds, pharmaceutical compositions thereof, and method of treating microbial infections are also provided.
  [FR] L'invention concerne des composés aromatiques substitués de formule générale (I), qui sont des inhibiteurs de l'ARNt synthétase, et qui peuvent ainsi être utilisés en tant qu'agents antimicrobiens. Les composés de l'invention peuvent être utilisés pour le traitement ou la prévention d'un état causé ou induit par des bactéries anaérobies Gram-positives, Gram-négatives ou des organismes fongiques de ce type, plus particulièrement contre une bactérie de type Staphylococci, Enterococci, Streptococci, Haemophilus, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillusou Enterobactericeae ; et des organismes fongiques de type Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Paecilomyces, Paracoccidiodes, Pneumocystis, Trichophyton, ou Trichosporium. L'invention concerne également des procédés de préparation desdits composés, des compositions pharmaceutiques les comprenant, et une méthode de traitement d'infections microbiennes.